- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN2176-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,567
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intracranial Meningioma
- Interventions
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- Drug · Other
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 17
- States / cities
- Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
- Conditions
- Body Weight Changes
- Interventions
- MicroDiet, Healthy Diet
- Behavioral
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- X Linked Myotubular Myopathy
- Interventions
- ApoTamox 10mg, Placebo
- Drug
- Lead sponsor
- James Dowling
- Other
- Eligibility
- 6 Months and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rockville, Maryland
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Bitopertin, Placebo, SSRI
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 27
- States / cities
- Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
- Conditions
- Post Operative Surgical Site Infection
- Interventions
- Standard of care, Vancomycin and Tobramycin
- Drug
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 31
- States / cities
- Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
- Conditions
- Asthma
- Interventions
- MEMP1972A, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Bakersfield, California • Costa Mesa, California + 46 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
- Interventions
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
- Interventions
- 25% IV albumin, Placebo
- Biological · Other
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- EUR-1100, placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Kidney Failure
- Interventions
- Tacrolimus, Everolimus
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Cream Supplement group
- Dietary Supplement
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 14 Days
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 7
- States / cities
- Orlando, Florida • East Lansing, Michigan • Boardman, Ohio + 4 more
- Conditions
- Hypertension, Pregnancy-Induced
- Interventions
- Acetaminophen, Ibuprofen
- Drug
- Lead sponsor
- MemorialCare Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- TAK-755, Standard of care
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
- Conditions
- HIV Infections
- Interventions
- GW695634
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Fountain Valley, California • San Francisco, California + 15 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Device: Omnipod M System with study CGM, Standard Therapy plus study CGM
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Barbara, California + 23 more
- Conditions
- Diabetes Mellitus
- Interventions
- IDegLira, Insulin Degludec (U-100), Insulin Aspart
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 39
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
- Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more
- Conditions
- Multiple Sclerosis, Hypertension
- Interventions
- Home-based aerobic training
- Behavioral
- Lead sponsor
- University of Massachusetts, Boston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cesarean Section Complications
- Interventions
- Erector Spinae Plane (ESP) Block, bupivacaine liposome injectable suspension, bupivacaine
- Procedure · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Athletic Performance, Recovery, Sleep
- Interventions
- Magnesium glycinate, Magnesium L-threonate, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Early Stage Breast Cancer (Stage 0-III)
- Interventions
- Exercise Regimen
- Other
- Lead sponsor
- Nevada Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada